ReviewInternational journal of nanomedicine2026
The Dual-Faceted Role of Metal-Based Nanomaterials in Hepatic Fibrosis Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing anti-fibrotic therapy: nanomedicine approaches to overcome current limitations.Materials today. Bio · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic fibrosis represents a pivotal transitional stage between hepatitis and cirrhosis or hepatocellular carcinoma, predominantly mediated by hepatic stellate cells (HSCs) activation, dysregulated extracellular matrix (ECM) deposition, and oxidative stress. Metal-based nanomaterials (MNMs) exhibit dualistic effects in liver fibrosis progression, owing to their high specific surface area, tunable morphology, surface functionalization potential, and quantum properties. On the one hand, MNMs hold substantial therapeutic and diagnostic potential: they enable precise targeted drug delivery (passive/active targeting to HSCs or hepatocytes), synergize with natural products to enhance bioavailability and multifaceted antifibrotic efficacy, remodel the fibrotic microenvironment via nanozyme-mediated reactive oxygen species (ROS) scavenging and hypoxia alleviation, and serve as core components of integrated theranostic platforms for noninvasive imaging and real-time treatment monitoring. Specifically, pure metals (Au, Pt), metal oxides (CeO
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.